PFIZi028-A
B212c7
iPSC line
At European Collection of Authenticated Cell Cultures (ECACC)
Timepoint: 48hr post thaw
Magnification: x4
Magnification: x4
Timepoint: 48hr post thaw
Magnification: x10
Magnification: x10
Timepoint: Confluency
Magnification: x4
Magnification: x4
Timepoint: Confluency
Magnification: x10
Magnification: x10
A CLIP contains information about a cell line including any
specific third party obligations relating to, for example,
licensing obligations or the donor consent which affect the
use of the cell line.
A batch specific Certificate of Analysis will be available to
download once you receive your EBiSC iPSC line.
General#
Cell Line |
|
| hPSCreg Name | PFIZi028-A |
| Alternative name(s) |
B212c7
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
UKKi027-A (NP0101-A, NP0101-3D) UKKi027-C (NP0101-C, NP0101-10H) UKKi028-A (NP0115-A, NP0115-4) UKKi028-B (NP0115-B) UKKi028-C (NP0115-C) UKKi036-A (NP0143-A, NP0143-5) UKKi026-C (NP0114-5E) UKKi035-B (NP0139-B, NP0139-6C) Donor's gene variants: MYBPC3, MYBPC3 Donor diseases: Hypertrophic cardiomyopathy UKKi037-C (NP0144-C, NP0144-41) UKKi026-A (NP0114-1A) UKKi006-A (D4-cB, M4C4, NP0053-5) UKKi007-A (NP0014-6, UKK007Ai) Donor's gene variants: RYR2, RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia UKKi007-B (NP0014-5) Donor's gene variants: RYR2 Donor diseases: Catecholaminergic polymorphic ventricular tachycardia UNEWi002-A (UNEW002Ai, PRPF31 AW) Donor's gene variants: PRPF31, PRPF31 Donor diseases: Retinitis pigmentosa UKBi005-A (iLB-C-31f-r1, LB-31-1) UKBi007-A (LB-33-5, iLB-MJD3-33f-r5) Donor's gene variants: ATXN3, ATXN3 Donor diseases: Spinocerebellar ataxia type 3 EDi001-A (AST22, AST23, SAMEA3319992) Donor's gene variants: SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi002-A (NAS2) WTSIi003-A (HPSI1213i-hehd_2) WTSIi005-A (HPSI1113i-podx_1) |
Provider |
|
| Depositor | Pfizer Limited - Pfizer (PFIZ) |
| Distributors |
EBiSC
European Collection of Authenticated Cell Cultures (ECACC)
|
External Databases |
|
| hPSCreg | PFIZi028-A |
| BioSamples | SAMEA104491452 |
| ECACC | 66540639 |
| Cellosaurus | CVCL_VE76 |
| CLO | CLO_0101713 |
| Wikidata | Q54947282 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information#
General Donor Information |
|
| Sex | female |
| Age of donor (at collection) | 5-9 |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA104491451 |
hIPSC Derivation#
General |
|
| Source cell type |
peripheral blood mononuclear cellA leukocyte with a single non-segmented nucleus in the mature form found in the circulatory pool of blood.
|
| Age of donor (at collection) | 5-9 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
| Genes | |
| Is reprogramming vector detectable? |
No |
| Methods used |
RT-PCR
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
Culture Conditions#
Latest released batch |
|
| Culture medium | mTeSR™1 |
| Passage method | EDTA |
| Surface coating | matrigel / Geltrex |
| O2 concentration | 21 |
| CO2 concentration | 5 |
| Temperature | 37 |
The following are the depositor culture conditions, they do not refer to any specific batch.
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
EDTA
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium |
mTeSR™ 1
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | No |
Characterisation#
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| SSEA-1 |
No |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Sterility |
|
| Inoculation for microbiological growth | No Contaminants Detected |
| Mycoplasma | Not Detected |
| Viability | Viable post-cryopreservation |
Genotyping#
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46, XX; Modal karyotype in 20 cells showed a normal female chromosome complement and banding pattern
Passage number: 12
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|